Lecanemab winner in two categories at The Scrip Awards 2023 November 20, 2023 08:30 Non Regulatory Read more
Invitation to presentation of BioArctic’s third quarter report for July – September 2023 on November 8 at 9.30 a.m. CET November 1, 2023 08:30 Non Regulatory Read more
New data from LEQEMBI® (lecanemab-irmb) phase 3 Clarity AD study and subcutaneous formulation presented at CTAD October 25, 2023 23:25 Non Regulatory Read more
Lecanemab named one of the world’s best inventions in 2023 by TIME October 24, 2023 16:50 Non Regulatory Read more
New data from LEQEMBI® (lecanemab-irmb) phase 3 Clarity AD study and subcutaneous formulation to be presented at CTAD October 16, 2023 08:00 Non Regulatory Read more
BioArctic receives patent in Japan for new antibodies targeting Parkinson’s disease August 23, 2023 10:45 Non Regulatory Read more
Latest analysis of lecanemab’s effect on biomarkers as well as new data on subcutaneous dosing presented at the AAIC 2023 Alzheimer conference July 20, 2023 01:30 Non Regulatory Read more
Latest data on lecanemab to be presented at Alzheimer’s Association International Conference (AAIC) 2023 July 12, 2023 01:30 Non Regulatory Read more
Invitation to presentation of BioArctic’s second quarter report for April – June 2023 on July 12 at 9.30 a.m. CET July 5, 2023 08:30 Non Regulatory Read more
Marketing Authorization Application for lecanemab as treatment for early Alzheimer’s disease filed in South Korea June 8, 2023 01:30 Non Regulatory Read more
Marketing Authorisation Application for lecanemab submitted in Great Britain May 22, 2023 01:30 Non Regulatory Read more
Societal value of lecanemab in Japan published in Neurology and Therapy May 17, 2023 01:30 Non Regulatory Read more
Health Canada accepts New Drug Submission for lecanemab as treatment for early Alzheimer’s disease May 16, 2023 01:30 Non Regulatory Read more
Invitation to presentation of BioArctic’s first quarter report for January – March 2023 on April 27 at 9.30 a.m. CET April 19, 2023 08:30 Non Regulatory Read more
Long-term health outcomes for lecanemab using simulation model and Phase 3 Clarity AD data published April 4, 2023 01:30 Non Regulatory Read more
New lecanemab-data presented at the AD/PD™ 2023 conference April 3, 2023 08:00 Non Regulatory Read more
Eisai publishes additional detailed analyses from lecanemab phase 2b study March 31, 2023 08:00 Non Regulatory Read more
New lecanemab-data to be presented at the AD/PD™ 2023 conference March 23, 2023 08:00 Non Regulatory Read more
Eisai publishes societal value of lecanemab using phase 3 Clarity AD data in peer-reviewed Neurology and Therapy journal March 20, 2023 00:30 Non Regulatory Read more
U.S. Veterans’ Health Administration (VHA) provides coverage of LEQEMBI™ (lecanemab-irmb) for veterans living with early stages of Alzheimer’s disease March 13, 2023 20:30 Non Regulatory Read more
Biologics License Application for lecanemab designated for Priority Review by China National Medical Products Administration February 28, 2023 00:30 Non Regulatory Read more
Invitation to presentation of BioArctic’s fourth quarter report for October – December 2022 on February 3 at 9.30 a.m. CET January 25, 2023 08:30 Non Regulatory Read more
BioArctic’s partner Eisai submits supplemental Biologics License Application to FDA for traditional approval of LEQEMBI™ (lecanemab-irmb) for the treatment of Alzheimer’s disease January 7, 2023 05:30 Non Regulatory Read more
BioArctic’s partner Eisai publishes statement relating to article on lecanemab in Scienceinsider December 23, 2022 08:45 Non Regulatory Read more
BioArctic’s partner Eisai initiates BLA submission of data for lecanemab in China December 23, 2022 00:30 Non Regulatory Read more
Results from lecanemab confirmatory phase 3 Clarity AD study to be presented at 15th Clinical Trials on Alzheimer’s Disease (CTAD) conference November 21, 2022 08:00 Non Regulatory Read more
BioArctic expands portfolio with alpha-synuclein Brain Transporter project November 17, 2022 08:00 Non Regulatory Read more
BioArctic receives new patent in the US for blood-brain barrier transport technology November 14, 2022 08:00 Non Regulatory Read more
BioArctic develops new treatment for Gaucher’s disease November 8, 2022 08:00 Non Regulatory Read more
Invitation to presentation of BioArctic’s third quarter report for July – September 2022 on October 20 at 9.30 a.m. CET October 14, 2022 08:30 Non Regulatory Read more
Latest data on lecanemab presented at Alzheimer’s Association International Conference (AAIC) August 5, 2022 08:00 Non Regulatory Read more
Latest data on lecanemab to be presented at Alzheimer’s Association International Conference (AAIC) July 26, 2022 08:00 Non Regulatory Read more
Invitation to presentation of BioArctic’s second quarter report for April – June 2022 on July 12 at 9.30 a.m. CET July 5, 2022 08:00 Non Regulatory Read more
BioArctic receives new drug substance patent in the US for ABBV-0805 against Parkinson’s disease May 6, 2022 08:50 Non Regulatory Read more
Modeling published in Neurology and Therapy suggests that lecanemab could delay progression to Alzheimer’s dementia by several years April 27, 2022 08:00 Non Regulatory Read more
Invitation to presentation of BioArctic’s First Quarter Report for January – March 2022 on April 28 at 9.30 a.m. CET April 20, 2022 08:00 Non Regulatory Read more
BioArctic and Eisai presented latest data regarding lecanemab at the AD/PD[TM] 2022 conference March 21, 2022 19:54 Non Regulatory Read more
Latest lecanemab data to be presented at the AD/PD™ congress March 11, 2022 08:00 Non Regulatory Read more
BioArctic continues to build its commercial organization February 18, 2022 08:00 Non Regulatory Read more
Invitation to presentation of BioArctic’s Full Year Report for January – December 2021 on February 3 at 9.30 a.m. CET January 27, 2022 08:00 Non Regulatory Read more
DIAN-TU enrolls first subject for the Tau NexGen study with lecanemab as back-ground anti-amyloid treatment January 19, 2022 08:00 Non Regulatory Read more
New data on lecanemab presented at the CTAD Alzheimer conference November 15, 2021 08:00 Non Regulatory Read more
DIAN-TU selects lecanemab for clinical trial for dominantly inherited Alzheimer’s disease November 8, 2021 18:00 Non Regulatory Read more
New data published on ABBV-0805 in Neurobiology of Disease November 8, 2021 08:00 Non Regulatory Read more
New data on lecanemab to be presented at the 14[th] Clinical Trials on Alzheimer’s Disease (CTAD) conference November 4, 2021 08:00 Non Regulatory Read more
Invitation to presentation of BioArctic’s Interim Report for the period January – September 2021 on October 21 at 9.30 a.m. CET October 11, 2021 11:00 Non Regulatory Read more
New data presented at MDS Congress of ABBV-0805 in Parkinson’s disease September 10, 2021 16:40 Non Regulatory Read more
Eisai presented latest data from the lecanemab clinical program at AAIC 2021 July 30, 2021 08:00 Non Regulatory Read more
Latest data on lecanemab to be presented at Alzheimer’s Association International Conference (AAIC) July 21, 2021 08:00 Non Regulatory Read more
BioArctic receives patent in Japan for new antibodies targeting Alzheimer’s disease May 11, 2021 08:00 Non Regulatory Read more
Lecanemab (BAN2401) Phase 2b study in early Alzheimer’s disease published in peer-reviewed journal, Alzheimer’s Research & Therapy April 20, 2021 08:00 Non Regulatory Read more
Invitation to presentation of BioArctic’s Interim Report for the period January – March 2021 on April 21 at 9.30 a.m. CET April 15, 2021 08:00 Non Regulatory Read more
BioArctic and Eisai presented latest data regarding lecanemab at AD/PD 2021 March 15, 2021 08:00 Non Regulatory Read more
Latest lecanemab data to be presented at the AD/PD™ congress March 5, 2021 08:00 Non Regulatory Read more
Eisai increases the number of participants in Clarity AD study February 3, 2021 08:05 Non Regulatory Read more
BioArctic receives European patent for new antibodies targeting Alzheimer’s disease January 27, 2021 08:00 Non Regulatory Read more
Invitation to presentation of BioArctic’s Full Year Report for the period January – December 2020 on February 4 at 9.30 a.m. CET January 26, 2021 08:00 Non Regulatory Read more
Eisai presented latest data regarding drug candidate BAN2401 at CTAD 2020 November 9, 2020 08:00 Non Regulatory Read more
BioArctic’s partner Eisai to present latest data on BAN2401 at CTAD conference October 28, 2020 08:00 Non Regulatory Read more
Invitation to presentation of BioArctic’s Interim Report for the period January – September 2020 on October 14 at 9.30 a.m. CET October 6, 2020 08:30 Non Regulatory Read more
Eisai presents the latest data from the Phase 2b open-label extension study of BAN2401 at AAIC 2020 July 30, 2020 10:00 Non Regulatory Read more
BioArctic’s partner Eisai to present update on the development of BAN2401 at Alzheimer’s Association International Conference 2020 July 22, 2020 08:00 Non Regulatory Read more
New global Phase 3 program of BAN2401 initiated in preclinical (asymptomatic) Alzheimer’s disease July 14, 2020 08:00 Non Regulatory Read more
BioArctic and University of Oslo sign research agreement to investigate Apolipoprotein E as a drug target for Alzheimer’s disease June 29, 2020 08:30 Non Regulatory Read more
Alzheimer patients at Swedish clinics to be included in Phase 3 study of drug candidate BAN2401 March 3, 2020 08:00 Non Regulatory Read more
Invitation to presentation of BioArctic’s Full Year Report for the period January – December 2019 on February 6 at 9.30 a.m. CET January 28, 2020 08:30 Non Regulatory Read more
BioArctic strengthens its management team with two strategic recruitments December 10, 2019 10:19 Non Regulatory Read more
BioArctic and Eisai to present data on BAN2401 at the Clinical Trials on Alzheimer’s Disease conference December 2, 2019 08:00 Non Regulatory Read more
Invitation to presentation of BioArctic’s Interim Report for the period January – September 2019 on October 24 at 9.30 a.m. CET October 16, 2019 08:30 Non Regulatory Read more
BioArctic and Eisai present new data regarding BAN2401 at the Alzheimer’s Association International Conference 2019 July 18, 2019 07:00 Non Regulatory Read more
BioArctic’s co-founder received AAIC Lifetime Achievement Award July 15, 2019 17:00 Non Regulatory Read more
BioArctic and Eisai to present BAN2401 at the Alzheimer’s Association International Conference 2019 July 11, 2019 07:30 Non Regulatory Read more
Invitation to presentation of BioArctic’s Interim Report for the second quarter of 2019 on July 11 at 9.30 a.m. CET July 2, 2019 08:30 Non Regulatory Read more
BioArctic strengthens its blood-brain barrier technology platform with world leading scientist recruitment May 23, 2019 08:00 Non Regulatory Read more
BioArctic: Alzheimer’s Clinical Trials Consortium and Eisai announce BAN2401 to be evaluated in clinical study for prevention of Alzheimer’s disease May 10, 2019 09:30 Non Regulatory Read more
BioArctic’s Board of Directors and management increase their shareholdings May 9, 2019 19:30 Non Regulatory Read more
Invitation to presentation of BioArctic’s Interim Report for the first quarter of 2019 on May 9, at 9.30 a.m. CET April 29, 2019 08:00 Non Regulatory Read more
BioArctic receives grant from Vinnova for a collaborative research project to increase brain uptake of antibodies April 3, 2019 15:45 Non Regulatory Read more
BioArctic’s partner Eisai to give poster presentations on BAN2401 in early Alzheimer’s disease at the AD/PD conference in Lisbon March 25, 2019 08:00 Non Regulatory Read more
Invitation to presentation of BioArctic’s Full Year Report 2018 on February 14, 2019 February 7, 2019 09:15 Non Regulatory Read more
BioArctic employs Gunilla Andersson as Senior Director HR December 19, 2018 08:00 Non Regulatory Read more
BioArctic to present at Jefferies 2018 London Healthcare Conference on November 15 November 13, 2018 08:00 Non Regulatory Read more
Invitation to presentation of BioArctic’s Interim Report for the period January – September 2018 on November 8, 2018 October 30, 2018 09:15 Non Regulatory Read more
BioArctic: Eisai to present additional data from BAN2401 Phase 2b study in early Alzheimer’s disease and the presentation will be webcast live from CTAD October 18, 2018 01:30 Non Regulatory Read more
Invitation to presentation of BioArctic’s Interim Report for the period January – June 2018 on August 23, 2018 August 14, 2018 08:00 Non Regulatory Read more
Invitation to presentation of BioArctic’s Interim Report January – March 2018 on April 26, 2018 April 12, 2018 08:00 Non Regulatory Read more
EXERCISE OF OVER-ALLOTMENT OPTION AND END OF THE STABILIZATION PERIOD November 6, 2017 20:00 Non Regulatory Read more
Invitation to presentation of BioArctic’s Interim Report January – September 2017 on November 8 November 3, 2017 10:00 Non Regulatory Read more
Trading in BioArctic’s B-shares commences today on Nasdaq Stockholm October 12, 2017 08:00 Non Regulatory Read more
